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Abstract
Background: Intermittent preventive treatment of malaria during pregnancy (IPTp) with dihydroartemisinin-
piperaquine (DP) significantly reduces the burden of malaria during pregnancy compared to sulfadoxine-
pyrimethamine (SP), the current standard of care, but its impact on the incidence of malaria during infancy is
unknown.
Methods: We conducted a double-blind randomized trial to compare the incidence of malaria during infancy
among infants born to HIV-uninfected pregnant women who were randomized to monthly IPTp with either DP or
SP. Infants were followed for all their medical care in a dedicated study clinic, and routine assessments were
conducted every 4 weeks. At all visits, infants with fever and a positive thick blood smear were diagnosed and
treated for malaria. The primary outcome was malaria incidence during the first 12 months of life. All analyses were
done by modified intention to treat.
Results: Of the 782 women enrolled, 687 were followed through delivery from December 9, 2016, to December 5,
2017, resulting in 678 live births: 339 born to mothers randomized to SP and 339 born to those randomized to DP.
Of these, 581 infants (85.7%) were followed up to 12 months of age. Overall, the incidence of malaria was lower
among infants born to mothers randomized to DP compared to SP, but the difference was not statistically
significant (1.71 vs 1.98 episodes per person-year, incidence rate ratio (IRR) 0.87, 95% confidence interval (CI) 0.73–
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1.03, p = 0.11). Stratifying by infant sex, IPTp with DP was associated with a lower incidence of malaria among male
infants (IRR 0.75, 95% CI 0.58–0.98, p = 0.03) but not female infants (IRR 0.99, 95% CI 0.79–1.24, p = 0.93).
Conclusion: Despite the superiority of DP for IPTp, there was no evidence of a difference in malaria incidence
during infancy in infants born to mothers who received DP compared to those born to mothers who received SP.
Only male infants appeared to benefit from IPTp-DP suggesting that IPTp-DP may provide additional benefits
beyond birth. Further research is needed to further explore the benefits of DP versus SP for IPTp on the health
outcomes of infants.
Trial registration: ClinicalTrials.gov, NCT02793622. Registered on June 8, 2016.
Keywords: Malaria, Intermittent preventive treatment, Pregnancy, Sulfadoxine-pyrimethamine, Dihydroartemisinin-
piperaquine, Infants
Background
Infection with malaria parasites during pregnancy re-
mains a major public health problem, especially in sub-
Saharan Africa where transmission intensity is highest
and Plasmodium falciparum the predominant species. In
2018, there were an estimated 39 million pregnancies in
sub-Saharan Africa, of which over 11 million (29%) were
exposed to P. falciparum [1]. The majority of women
residing in malaria-endemic areas of sub-Saharan Africa
are partially immune and do not develop symptoms
when infected with P. falciparum during pregnancy.
However, even in the absence of symptomatic disease,
malaria in pregnancy is associated with maternal anemia
and adverse birth outcomes such as low birth weight,
preterm delivery, and stillbirth [2–4].
To prevent malaria in pregnancy and improve birth
outcomes, the World Health Organization (WHO) rec-
ommends intermittent preventive treatment (IPTp) with
sulfadoxine-pyrimethamine (SP) in pregnant women res-
iding in areas of moderate to high malaria transmission
intensity [5]. However, the effectiveness of IPTp-SP is
threatened by widespread antifolate resistance resulting
in failure to clear parasites and prevent new infections
[6]. Recent studies have shown dihydroartemisinin-
piperaquine (DP) to be a promising alternative to SP for
IPTp. Compared to IPTp-SP, IPTp-DP has been shown
to be much more effective at reducing the prevalence of
malaria parasitemia and incidence of clinical malaria
during pregnancy and reducing the risk of placental mal-
aria at delivery [7–9]. However, despite significantly re-
ducing the burden of malaria during pregnancy, IPTp-
DP has not been shown to be superior to IPTp-SP at im-
proving adverse birth outcomes [7–9].
Prevention of malaria during pregnancy may have add-
itional benefits to the infant beyond the neonatal period.
Studies have shown that intrauterine exposure to P. fal-
ciparum may negatively affect the development of anti-
malarial immunity in the infant [10, 11]. Indeed, several
observational studies have suggested that placental mal-
aria increases the risk of malaria during infancy [12–14].
However, these studies could not rule out the possible
confounding effect of behavioral, environmental, genetic,
and social-economic factors shared by the mother and her
infant on the associations between exposure to malaria
parasites during pregnancy and risk of malaria during in-
fancy. A more robust method of testing this hypothesis
would be to compare the impact of a highly effective regi-
men versus a less effective regimen for IPTp on the risk of
malaria during infancy in a randomized controlled trial.
However, to date, clinical trials that have evaluated the im-
pact of IPTp on the risk of malaria during infancy have
been limited by little difference in the efficacy of IPTp reg-
imens [15, 16] or the provision of chemoprevention dur-
ing infancy, in addition to IPTp [17].
To address this gap in evidence, we compared the inci-
dence of malaria during the first year of life among in-
fants born to HIV-uninfected pregnant women who
took part in a double-blind randomized controlled trial
of monthly IPTp with DP (a highly effective regimen)
versus SP (a less effective regimen). During pregnancy,
IPTp-DP was superior to IPTp-SP at reducing the inci-
dence of clinical malaria and prevalence of asymptom-
atic parasitemia during pregnancy, and the prevalence of
placental malaria at delivery [9]. Children born to
mothers enrolled in this study did not receive chemopre-
vention during infancy.
Methods
Study setting and participants
This study was conducted from September 6, 2016, to
December 4, 2018, in Busia district, south-eastern
Uganda, an area of high malaria transmission intensity.
The study was conducted in two phases: the pregnancy
phase, which involved enrollment and follow-up of preg-
nant women through delivery, and the infancy phase,
which involved follow-up of infants through 12months
of age. Details of the pregnancy phase of the study have
been published elsewhere [9]. In brief, HIV-uninfected
pregnant women were eligible for enrollment if they
were 12–20 weeks of gestation, 16 years or older, agreed
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to come to the study clinic for any illness, had no history
of taking IPTp-SP or any other antimalarial therapy dur-
ing the current pregnancy, and provided written informed
consent. Women were excluded if they had a history of
serious adverse events to SP or DP. The infancy phase in-
volved the follow-up of all live births among women en-
rolled in the pregnancy phase of the study.
Study design, randomization, and masking
This was a double-blind randomized controlled trial de-
signed to assess the impact of monthly IPTp with DP
versus SP in HIV-uninfected pregnant women, on the
incidence of malaria during infancy (trial registration,
ClinicalTrials.gov; NCT02793622). At enrollment, preg-
nant women were randomly assigned in a 1:1 ratio to re-
ceive IPTp-DP or IPTp-SP. A randomization list was
computer generated using permuted blocks of 4 or 8 by
a staff member not directly involved in patient care. To
achieve allocation concealment, sealed envelopes, each
containing a treatment allocation number and treatment
group assignment, were prepared following the sequence
of the randomization list, prior to enrollment. Treatment
allocation was done by a study pharmacist not involved
in daily patient care by picking the next available sealed
envelope, recording the participant’s identification num-
ber on the envelope, and opening it to reveal the
assigned treatment. The treatment allocation number,
the participant’s identification number, and the assigned
treatment were then recorded on a treatment allocation
log which was kept in a safe lockable place only access-
ible by the study pharmacist. Study drugs for each en-
rolled participant were pre-packaged by the study
pharmacist and labeled with the participant’s identifica-
tion number. Study drugs were administered every 4
weeks starting at 16 or 20 weeks of gestation. Each dose
of DP (tablets of 40 mg of dihydroartemisinin and 320
mg of piperaquine; Duo-Cotexin, Holley-Cotec, Beijing,
China) consisted of 3 tablets given once a day for 3 con-
secutive days. Each dose of SP (tablets of 500 mg of sul-
fadoxine and 25mg of pyrimethamine; Kamsidar,
Kampala Pharmaceutical Industries) consisted of 3 tab-
lets given as a single dose. To achieve blinding, partici-
pants randomized to DP also received SP placebos, and
participants randomized to SP received DP placebos
every 4 weeks. The administration of all 1st daily doses
of study drugs was directly observed in the study clinic.
The 2nd and 3rd daily doses were dispensed to the
mother for self-administration at home. Adherence to
the 2nd and 3rd daily doses was assessed by self-
reporting during the visits following routine visits.
Study procedures
Study procedures for pregnant women have been previ-
ously described in detail [9]. Briefly, at enrollment, all
participants received a long-lasting insecticide-treated
net and underwent a standard history and physical
examination. Pregnant women were encouraged to come
to a dedicated study clinic any time they were ill and to
attend routine visits conducted every 4 weeks for study
drug dispensing and laboratory testing. Pregnant women
diagnosed with symptomatic malaria detected by micros-
copy at any visit were treated with artemether-
lumefantrine. Asymptomatic parasitemia detected during
routine visits was not treated. At delivery, a standardized
assessment was completed including evaluation of birth
weight, gestation age based on ultrasound dating, and
collection of biological specimens including placental tis-
sue and placental blood.
Following delivery, all live births were followed up to
12months of age. Mothers were encouraged to bring
their infants to a dedicated study clinic open every day
for all their medical care and were provided a transport
refund. Routine assessments were conducted every 4
weeks including the collection of blood for the detection
of parasites by microscopy. Infants who presented with a
history of fever in the past 24 h or with a documented
tympanic temperature > 38.0 °C had blood collected for
a thick blood smear. If the thick blood smear was posi-
tive, infants were treated for malaria according to the
Uganda Ministry of Health guidelines which consisted of
artemether-lumefantrine for uncomplicated malaria and
intravenous artesunate for complicated malaria. Non-
malarial illnesses were treated according to the inte-
grated management of childhood illnesses guidelines. At
12, 28, and 52 weeks of age, blood was collected for
hemoglobin measurement.
Laboratory procedures
The presence of malaria parasites in dried placental
blood spots was detected by loop-mediated isothermal
amplification as previously described [18]. Placental mal-
aria by histology defined as the presence of malaria para-
sites or malaria pigment was detected from placental
tissue as previously described [19]. Blood smears were
stained with 2% Giemsa and read by experienced mi-
croscopists. A blood smear was considered negative
when the examination of 100 high-power fields did not
reveal asexual parasites. All blood smears were read by
two independent microscopists. Blood smears with dis-
crepant results between the first and the second readers
were read by a third reader as a tiebreaker. Hemoglobin
measurements were made using a portable spectropho-
tometer (Hemocue, Angelholm, Sweden).
Study outcomes
The primary outcome was the incidence of malaria from
birth to 12months of age. An incident episode of mal-
aria was defined as the presence of fever (history of fever
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in the past 24 h or a tympanic temperature ≥ 38.0 °C)
with a positive thick blood smear not preceded by an-
other malaria episode in the last 14 days. Secondary out-
comes included time to the first episode of malaria,
incidence of complicated malaria defined as an episode
of malaria with danger signs (any of the following, less
than 3 convulsions over 24 h, inability to sit or stand,
vomiting everything, unable to breastfeed or drink) or
the meeting standardized criteria for severe malaria, inci-
dence of all-cause hospitalizations, infant mortality, inci-
dence of non-malarial febrile illnesses, prevalence of
malaria parasitemia during routine visits, and prevalence
of anemia (hemoglobin < 10 g/dL) at 12, 28, and 52
weeks of age.
Statistical analysis
To test the hypothesis that infants born to mothers ran-
domized to IPTp-DP would have a lower incidence of
malaria during the first 12 months of life compared to
infants born to mothers randomized to IPTp-SP, it was
estimated that the incidence of malaria in infants born
to mothers randomized to IPTp-SP would be 3–5 epi-
sodes per person-year (using data from a prior study
conducted in the adjacent district of Tororo [20] and a
loss of 5% of follow-up time per year). With these as-
sumptions, the study had 80% power to detect an 18–
23% difference in the incidence of malaria (incidence
rate ratio of 0.77–0.82) among infants born to mothers
randomized to IPTp-DP compared to those born to
mothers randomized to IPTp-SP with a two-sided sig-
nificance level of 0.05.
Data were double entered and verified in Microsoft
Access by two independent data entrants. Using Stata,
version 14.2, statistical analyses were done in the modi-
fied intention-to-treat population, which included all live
births followed until they reached 12 months of age or
premature study withdrawal. Comparisons of simple
proportions were made using the chi-square test or Fish-
er’s exact test. Comparisons of continuous variables were
made using the t test. Comparisons of proportions with
repeated measures were made with generalized estimat-
ing equations, with the use of log-binomial regression
and robust standard errors to adjust for clustering. Com-
parisons of incidence measures were made using a nega-
tive binomial regression model. Incidence rate ratios
(IRRs) were defined as the incidence in the IPTp-DP
arm divided by the incidence in the IPTp-SP arm. Preva-
lence ratios were defined as the prevalence in the IPTp-
DP arm divided by the prevalence in the IPTp-SP arm.
Stratified analyses of our primary outcome according to
infant sex and age, and maternal gravidity were planned
a priori in the statistical analysis plan. The cumulative
risk of the first episode of malaria was compared using a
Cox proportional hazards model with the association
expressed as the hazard ratio (HR). In all analyses, two-
sided p values of < 0.05 were considered statistically
significant.
Results
Study participants and follow-up
Between September 2016 and May 2017, 879 pregnant
women were screened and 782 were enrolled and ran-
domized to receive either monthly IPTp with DP (N =
391) or SP (N = 391) (Fig. 1) [9]. Among the 687 (87.9%)
women who were followed through delivery, there were
678 live births from December 9, 2016, to December 5,
2017, 339 in the IPTp-DP group and 339 in the IPTp-SP
group. Among the 678 live births, 581 infants (85.7%)
were followed up to 12 months of age (Fig. 1). Maternal
characteristics at enrollment were similar between the
two groups (Table 1). Mean age at enrollment was 23.9
years, 321 (47.3%) infants were born to primigravida or
secundigravida mothers, and 399 (58.8%) infants were
born to mothers enrolled at 12–16 weeks of gestation
while 279 (41.2%) were born to mothers enrolled at >
16–20 weeks of gestation. Three hundred fifty-three
(52.1%) infants were born to mothers with parasitemia
detected by microscopy at enrollment. During preg-
nancy, the period prevalence of parasitemia detected by
microscopy during routine visits was significantly lower
in mothers who received IPTp-DP (365/2324, 15.7%)
compared to mothers who received IPTp-SP (828/2291,
36.1%, p < 0.001). Similarly, the incidence of malaria dur-
ing pregnancy was significantly lower in mothers who
received IPTp-DP compared to mothers who received
IPTp-SP (0.09 vs 0.59 episodes per person-year, p <
0.001). At delivery, compared to mothers who received
IPTp-SP, mothers who received IPTp-DP had a signifi-
cantly lower prevalence of placental parasitemia detected
by histology (28.3% vs 60.9%, p < 0.001, Table 1). How-
ever, at birth, there were no significant differences in the
characteristics of infants born to mothers who received
IPTp-DP or IPTp-SP (Table 1).
Impact of IPTp with DP on incidence of malaria in infancy
Overall, infants born into the cohort experienced 1131
episodes of malaria during 614 person-years of follow-
up. The incidence of malaria was lower among infants
born to mothers who received IPTp-DP (1.71 episodes
per person-year) compared to infants born to mothers
who received IPTp-SP (1.98 episodes per person-year),
but the difference was not statistically significant (inci-
dence rate ratio (IRR) 0.87, 95% confidence interval (CI)
0.73–1.03, p = 0.11; Table 2). However, the association
between IPTp and the incidence of malaria in infants
was modified by infant sex. Among male infants, the in-
cidence of malaria was significantly lower among infants
born to mothers who received IPTp-DP compared to
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those born to mothers who received IPTp-SP (IRR 0.75,
95% CI 0.58–0.98, p = 0.03). There was no difference in
the incidence of malaria between female infants born to
mothers who received IPTp-DP versus IPTp-SP (IRR
0.99, 95% CI 0.79–1.24, p = 0.93; Table 2). In addition,
the difference in malaria incidence between the IPTp
regimens among male infants was only significant be-
tween > 3 and 12months of age (IRR 0.73, 95% CI 0.56–
0.96, p = 0.02) but not between 0 and 3months of age
(IRR 0.89, 95% CI 0.48–1.66, p = 0.72). There were no
differences between the IPTp regimens among female
infants stratified by age (Table 2). There was no signifi-
cant difference in the time to the first episode of malaria
between infants born to mothers who received IPTp-DP
and infants born to mothers who received IPTp-SP (haz-
ard ratio (HR) 0.90, 95% CI 0.75–1.09, p = 0.30). When
stratified by infant sex, male infants born to mothers
who received IPTp-DP had a lower rate of the first epi-
sode of malaria compared to male infants born to
mothers who received IPTp-SP, but this did not reach
statistical significance (HR 0.79, 95% CI 0.60–1.05, p =
0.10) and there was no difference among female infants
(HR 1.01, 95% CI 0.78–1.31, p = 0.96; Fig. 2).
Impact of IPTp with DP on incidence of complicated
malaria in infancy
Overall, there were 68 episodes of complicated malaria
among 59 different infants. For 60 episodes of compli-
cated malaria, only danger signs were present while 8
episodes met the criteria for severe malaria (7 episodes
of respiratory distress and 1 episode of severe anemia).
The incidence of complicated malaria was lower among
infants born to mothers who received IPTp-DP com-
pared to those born to mothers who received IPTp-SP
(IRR = 0.54, 95% CI 0.32–0.92, p = 0.02; Table 3). Again,
effect modification by infant sex was observed. Male in-
fants born to mothers who received IPTp-DP had a sig-
nificantly lower incidence of complicated malaria
44 infants prematurely withdrawn
21 unable to locate for > 60 days
15 moved out of study area
7 died
1 withdrew informed consent
9 infants excluded
4 spontaneous abortions
5 stillbirths
53 infants prematurely withdrawn
18 unable to locate for > 60 days
17 moved out of study area
9 died
9 withdrew informed consent
339 live births included in the analyses
53 withdrawn prior to delivery
31 unable to locate for > 60 days
13 withdrew informed consent
8 moved out of study area
1 unable to comply with protocol
286 infants reached 12 months of age and 
completed follow-up
338 women followed through delivery resulting in 
348 infants delivered (10 sets of twins)
349 women followed through delivery resulting in 
352 infants delivered (3 sets of twins)
97 excluded during screening
33 prior antimalarial therapy given
23 HIV infected
16 gestational age > 20 weeks
7 intention of moving outside of study area
4 non-viable pregnancy
4 early or active labor
3 residence outside Busia District
2 history of adverse event to SP or DP
2 chronic medical condition
1 active medical problem requiring inpatient care
1 age < 16 years
1 does not plan to deliver in the hospital
295 infants reached 12 months of age and 
completed follow-up
879 women screened
13 infants excluded
10 spontaneous abortions
3 stillbirths
782 women enrolled
391 women randomised to monthly DP391 women randomised to monthly SP
42 withdrawn prior to delivery
19 unable to locate for > 60 days
11 withdrew informed consent
6 moved out of study area
5 unable to comply with protocol
1 became HIV infected
339 live births included in the analyses
Fig. 1 Trial profile. SP, sulfadoxine-pyrimethamine; DP, dihydroartemisinin-piperaquine
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compared to male infants born to mothers who received
IPTp-SP (IRR 0.36, 95% CI 0.17–0.78, p = 0.01). There
was no significant difference in the incidence of compli-
cated malaria between female infants born to mothers
who received IPTp-DP or IPTp-SP (IRR 0.86, 95% CI
0.40–1.87, p = 0.71).
Impact of IPTp with DP on other secondary outcomes
The incidence of all-cause hospitalizations was lower
among infants born to mothers who received IPTp-DP
compared to infants born to mothers who received
IPTp- SP, but this did not reach statistical significance
(IRR 0.39, 95% CI 0.15–1.05, p = 0.06). When stratified
by sex, male infants born to mothers who received
IPTp-DP had a statistically significantly lower incidence
of all-cause hospitalizations compared to male infants
born to mothers who received IPTp-SP (IRR 0.20, 95%
CI 0.05–0.82, p = 0.03), but there was no difference
among female infants (IRR 1.01, 95% CI 0.22–4.63, p =
0.99). A total of 16 infants died, including 9 in the neo-
natal period. One infant born to a mother who received
IPTp-DP died of malaria at 11 months of age. There was
no significant difference in the mortality rate between
infants born to mothers who received IPTp-DP or IPTp-
SP (IRR 0.45, 95% CI 0.03–7.88, p = 0.59). The incidence
of non-malarial febrile illnesses was similar among in-
fants born to mothers who received IPTp-DP or IPTp-
SP. The prevalence of parasitemia during routine visits
and prevalence of anemia (hemoglobin< 10 g/dL) mea-
sured at 12, 28, and 52 weeks of age were similar among
infants born to mothers who received IPTp-DP or IPTp-
SP. Considering the time to the first parasitemia, there
was no significant difference between infants born to
mothers who received IPTp-DP and those born to
mothers who received IPTp-SP (HR 0.92, 95% CI 0.76–
1.10, p = 0.37). When stratified by infant sex, male
Table 1 Characteristics of study participants and their mothers
Characteristic Maternal IPTp arm p value
Monthly SP (N = 339) Monthly DP (N = 339)
Maternal characteristics at enrollment
Age in years, mean (SD) 23.9 (5.9) 23.9 (5.7) 0.98
Gravidity, n (%)
Primigravida 86 (25.4%) 73 (21.5) 0.21
Secundigravida 72 (21.2%) 90 (26.6)
Multigravida 181 (53.4%) 176 (51.8)
Gestation age categories, n (%)
12–16 weeks 195 (57.5%) 204 (60.2%) 0.48
> 16–20 weeks 144 (42.5%) 135 (39.8%)
Parasite prevalence by microscopy, n (%) 170 (50.2%) 183 (54.0%) 0.32
Maternal characteristics during pregnancy
Parasite prevalence by microscopya, n/N (%) 828/2291 (36.1%) 365/2324 (15.7%) < 0.001
Incidence of malaria (episodes/PPY) 0.59 0.09 < 0.001
Measures of placental malaria
Placental blood positive by microscopyb, n/N (%) 29/326 (8.9%) 1/331 (0.3%) < 0.001
Placental blood positive by LAMPc, n/N (%) 71/320 (22.2%) 7/329 (2.1%) < 0.001
Positive placental histologyd, n/N (%) 199/327 (60.9%) 93/329 (28.3%) < 0.001
Characteristics of infants at birth
Preterm birth, n (%) 27 (8.0%) 17 (5.0%) 0.12
Gestation age in weeks, mean (SD) 39.4 (1.9) 39.6 (1.6) 0.08
Low birth weight, n (%) 34 (10.0%) 26 (7.7%) 0.28
Birth weight in grams, mean (SD) 3052 (505) 3023 (408) 0.41
Female sex, n (%) 166 (49.0%) 180 (53.1%) 0.28
DP dihydroartemisinin-piperaquine, IPTp intermittent preventive treatment of malaria in pregnancy, LAMP loop-mediated isothermal amplification, PPY per person-
year, SD standard deviation, SP sulfadoxine-pyrimethamine
aDefined as the number of positive blood smears during routine visits divided by the total number of routine blood smears
bDefined as the detection of parasites in the placental blood by microscopy
cDefined as the detection of parasites in the placental blood by LAMP
dDefined as the detection of parasites or pigment in the placental tissue
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infants born to mothers who received IPTp-DP had a
slightly lower rate of first parasitemia compared to male
infants born to mothers who received IPTp-SP, but this
did not reach statistical significance (HR 0.81, 95% CI
0.62–1.06, p = 0.13) and there was no difference among
female infants (HR 1.02, 95% CI 0.79–1.31, p = 0.87).
Discussion
In this double-blind randomized controlled trial con-
ducted in an area of high malaria transmission intensity,
infants born to mothers randomized to IPTp-DP had a
13% lower incidence of malaria compared to infants
born to mothers randomized to IPTp-SP, but the differ-
ence was not statistically significant. However, among
male infants, IPTp-DP was associated with a lower inci-
dence of malaria compared to IPTp-SP. This difference
was primarily seen between > 3 and 12 months of age.
Similarly, male infants born to mothers who received
IPTp-DP had a lower incidence of complicated malaria
and all-cause hospitalizations compared to male infants
born to mothers who received IPTp-SP. In contrast,
among female infants, there were no differences in the
incidence of malaria, complicated malaria, and all-cause
hospitalizations between those born to mothers who re-
ceived IPTp-DP versus IPTp-SP. For both sexes, there
were no significant associations between maternal IPTp
regimen and the risk of non-malarial febrile illness or
anemia during infancy.
IPTp-DP remains an attractive alternative to IPTp-SP
for the prevention of malaria in HIV-uninfected preg-
nant women. Three randomized controlled trials con-
ducted recently in East Africa have consistently shown
that IPTp-DP is associated with significant reductions in
the risk of maternal parasitemia, maternal clinical mal-
aria, and placental malaria compared to IPTp-SP, yet
none of these studies has shown significant differences
in the risk of adverse birth outcomes for infants born to
mothers receiving DP or SP for IPTp [7–9]. Historically,
IPTp policy recommendations have been driven by evi-
dence supporting reductions in the risk of adverse birth
Table 2 Impact of IPTp on the incidence of malaria during infancy stratified by sex, age, and gravidity
Strata Maternal
IPTp arm
Number
of infants
Episodes
of malaria
Person-years
of follow-up
Incidence of
malaria (PPY)
IRR (95% CI) p value
All infants born alive SP 339 602 304.4 1.98 0.87 (0.73–1.03) 0.11
DP 339 529 309.2 1.71
Sex
Female infants SP 166 283 152.5 1.86 0.99 (0.79–1.24) 0.93
DP 180 303 164.8 1.84
Male infants SP 173 319 151.8 2.10 0.75 (0.58–0.98) 0.03
DP 159 226 144.3 1.57
Female infants stratified by age
0–3 months of age SP 166 30 40.1 0.75 1.16 (0.72–1.89) 0.54
DP 180 38 43.6 0.87
> 3–12months of age SP 156 253 112.5 2.25 0.97 (0.77–1.24) 0.83
DP 168 265 121.3 2.19
Male infants stratified by age
0–3 months of age SP 173 22 41.5 0.53 0.89 (0.48–1.66) 0.72
DP 159 18 38.2 0.47
> 3–12months of age SP 160 297 110.3 2.69 0.73 (0.56–0.96) 0.02
DP 145 208 106.1 1.96
Maternal gravidity
1 SP 86 131 69.3 1.89 0.84 (0.58–1.20) 0.33
DP 73 102 64.6 1.58
2 SP 72 97 65.5 1.48 1.04 (0.72–1.49) 0.85
DP 90 124 81.1 1.53
> 3 SP 181 374 169.5 2.21 0.84 (0.67–1.07) 0.15
DP 176 303 163.5 1.85
CI confidence interval, DP dihydroartemisinin-piperaquine, IPTp intermittent preventive treatment of malaria in pregnancy, IRR incidence rate ratio, PPY per person-
year, SP sulfadoxine-pyrimethamine
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outcomes, specifically low birth weight, and for this rea-
son, the WHO continues to recommend IPTp-SP [5].
However, improved protection from malaria infection
during pregnancy may have longer-term effects on infant
health [21]. A wealth of immunologic evidence suggests
that maternal malaria infection affects the development
of the fetal and infant immune system, both by altering
the immune graft received by the fetus (both maternal
antibodies and cells) as well as exposing the fetus to
parasite antigens that may alter both the innate and
adaptive immune responses [22]. Indeed, infants born to
mothers with placental malaria may be at an increased
risk of malaria during infancy, and it would be important
to know if more effective IPTp regimens could reduce
the risk of malaria in infants [13, 14].
In this study, although there was no overall evidence
of a reduced malaria incidence in infants born to
mothers receiving IPTp-DP versus IPTp-SP, our overall
findings suggest that IPTp-DP may be associated with a
moderately lower incidence of malaria in infants. A re-
cently published systematic review identified three ran-
domized controlled trials which evaluated the impact of
different IPTp regimens on malaria during infancy [23].
There were no significant differences in the incidence of
malaria among infants born to mothers randomized to
IPTp with mefloquine versus IPTp-SP [16], intermittent
screening and treatment with AL versus IPTp-SP [15],
or IPTp-SP versus placebo [14]. However, these studies
were limited by the failure of the alternative (non-SP)
regimen to significantly reduce the risk of placental mal-
aria. In a randomized controlled trial from Uganda,
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Kakuru et al. BMC Medicine          (2020) 18:207 Page 8 of 11
IPTp-DP was found to significantly reduce the risk of
placental malaria compared to IPTp-SP [8]. But, surpris-
ingly, the incidence of malaria during the first 2 years of
life in infants born into this cohort was higher in infants
born to mothers who received monthly IPTp-DP com-
pared to those born to mothers who received IPTp-SP
given every 2 months [17]. However, in that study, all in-
fants were also given DP every 3 months, and the associ-
ation between IPTp-DP and increased malaria during
infancy was only observed in females. This finding could
largely be explained by the fact that female infants with
in utero exposure to DP had lower piperaquine levels
after receiving DP during infancy, which is strongly pre-
dictive of malaria risk [24]. In contrast, among male in-
fants, in utero exposure to DP was not associated with
piperaquine levels during infancy [17]. Furthermore,
male infants born to mothers randomized to IPTp-DP
had a trend towards a lower incidence of malaria com-
pared to male infants born to mothers who received
IPTp-SP, a similar finding to that reported in here (aIRR
0.66, 95% CI 0.25–1.75) [17].
In the present study, IPTp-DP was associated with a
lower incidence of malaria, a lower incidence of compli-
cated malaria, and a lower incidence of all-cause hospi-
talizations during infancy compared to IPTp-SP, but
only among male infants. Although the precise mechan-
ism by which infant sex modifies the relationship be-
tween maternal IPTp, maternal malaria infection, and
infant malaria risk remains uncertain, there is a growing
body of evidence of sex-based differences in susceptibil-
ity to infectious diseases in infants [25, 26]. Male infants
have been found to have an increased predisposition to
more frequent and more severe manifestations of infec-
tious diseases than females [26]. Similarly, several ad-
verse pregnancy outcomes, including stillbirth, are more
common in males than in females [27]. This suggests
that in utero fetal exposures may have more severe con-
sequences for male infants than female infants [28]. Sev-
eral potential mechanisms for these sex-based
differences have been described. These include genetic
differences attributable to the heterogeneity of expres-
sion of X chromosome encoded genes [29], sex-
dependent differences in glucocorticoid receptor expres-
sion and fetal-placental responsivity to cortisol [30], and
sex-specific differences in neonatal and infant immune
responses to Toll-like receptor ligands and induction of
regulatory T cell populations [25, 31]. Given the reduced
risk of malaria among male infants whose mothers re-
ceived IPTp-DP compared to those whose mothers re-
ceived IPTp-SP, we hypothesize that effective prevention
of maternal malaria may prevent sex-specific adverse
consequences of placental malaria.
Our study had some limitations. The observed inci-
dence of malaria in infants born to mothers who re-
ceived IPTp-SP (1.98 episodes per person-year) was
lower than the assumed incidence of 3–5 episodes per
person per year which was used for sample size estima-
tion. This limited the power of the study to detect a sig-
nificant difference between the two IPTp arms if such a
difference truly existed. Also, our study was not powered
to conduct stratified analyses by infant sex and age, or to
test for associations between IPTp-DP and secondary
outcomes such as complicated malaria and all-cause
hospitalizations, which were relatively uncommon in our
Table 3 Secondary outcomes
Incidence measures Maternal IPTp arm Number of cases (incidence PPY) IRR (95% CI) p value
Complicated malaria SP 44 (0.145) 0.54 (0.32–0.92) 0.02
DP 24 (0.078)
All-cause hospitalisations SP 19 (0.062) 0.39 (0.15–1.05) 0.06
DP 8 (0.026)
Infant mortality SP 9 (0.030) 0.45 (0.03–7.88) 0.59
DP 7 (0.023)
Non-malarial febrile illnesses SP 1022 (3.36) 1.01 (0.91–1.12) 0.87
DP 1047 (3.39)
Prevalence measuresa Maternal IPTp arm Prevalence (%) PR (95% CI) p value
Parasitemiab SP 344/3879 (8.9%) 1.02 (0.83–1.27) 0.84
DP 357/3933 (9.1%)
Anemiac SP 222/878 (25.3%) 0.96 (0.79–1.17) 0.70
DP 216/892 (24.2%)
CI confidence interval, DP dihydroartemisinin-piperaquine, IPTp intermittent preventive treatment of malaria in pregnancy, IRR incidence rate ratio, PPY per person-
year, PR prevalence ratio, SP sulfadoxine-pyrimethamine
aPrevalence measures are period prevalence
bProportion of blood smears with parasitemia measured routinely every 4 weeks starting at 4 weeks of age
cDefined as the proportion with hemoglobin < 10 g/dL measure routinely at 12, 28, and 52 weeks of age
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study. Therefore, statistically significant associations ob-
served in stratified analyses and between IPTp-DP and
secondary outcomes should be interpreted with caution.
This study was conducted in an area with very high mal-
aria transmission intensity, as at enrollment over 80% of
mothers had malaria parasitemia detected by microscopy
or quantitative PCR [9]. This limits the generalization of
our findings to other areas with lower transmission in-
tensity. Also, the administration of all SP doses was dir-
ectly observed while only the 1st daily dose of DP was
directly observed. It is possible that some mothers did
not take the 2nd and 3rd doses of DP which were dis-
pensed for self-administration at home. This could have
led to an underestimation of the effect of IPTp-DP com-
pared to SP on the incidence of malaria. Finally, we mea-
sured malaria incidence using passive surveillance which
could have underestimated the true incidence of malaria
if infants were treated for malaria at home or taken for
care outside the study clinic. However, mothers were en-
couraged to bring their infants to the study clinic for
care whenever they were sick and were provided a trans-
port refund.
Conclusion
In summary, our study findings show that in addition to
reducing the burden of malaria during pregnancy and
placental malaria at delivery compared to monthly IPTp-
SP [9], monthly IPTp-DP was associated with a reduced
incidence of malaria, complicated malaria, and a trend
towards a reduced incidence of all-cause hospitalizations
among male infants born to HIV-uninfected pregnant
women residing in a high malaria transmission setting.
Improved prevention of malaria during pregnancy may
have additional benefits beyond birth. These results pro-
vide additional support for replacing SP with DP for
IPTp in areas with widespread antifolate resistance. Fu-
ture studies of IPTp should consider follow-up of infants
beyond the neonatal period to evaluate the potential im-
pact of IPTp on infant outcomes, stratify results based
on infant sex, and evaluate the impact of IPTp on infant
outcomes in settings of moderate malaria transmission
intensity.
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